142 related articles for article (PubMed ID: 30604896)
1. GRB7 dependent proliferation of basal-like, HER-2 positive human breast cancer cell lines is mediated in part by HER-1 signaling.
Luoh SW; Wagoner W; Wang X; Hu Z; Lai X; Chin K; Sears R; Ramsey E
Mol Carcinog; 2019 May; 58(5):699-707. PubMed ID: 30604896
[TBL] [Abstract][Full Text] [Related]
2. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
[TBL] [Abstract][Full Text] [Related]
3. EGF-induced Grb7 recruits and promotes Ras activity essential for the tumorigenicity of Sk-Br3 breast cancer cells.
Chu PY; Li TK; Ding ST; Lai IR; Shen TL
J Biol Chem; 2010 Sep; 285(38):29279-85. PubMed ID: 20622016
[TBL] [Abstract][Full Text] [Related]
4. GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma.
Gotovac JR; Liu DS; Yates MJ; Milne JV; Macpherson AA; Simpson KJ; Eslick GD; Mitchell C; Duong CP; Phillips WA; Clemons NJ
J Pathol; 2020 Nov; 252(3):317-329. PubMed ID: 32737994
[TBL] [Abstract][Full Text] [Related]
5. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
Bai T; Luoh SW
Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
[TBL] [Abstract][Full Text] [Related]
6. GRB7 protein over-expression and clinical outcome in breast cancer.
Ramsey B; Bai T; Hanlon Newell A; Troxell M; Park B; Olson S; Keenan E; Luoh SW
Breast Cancer Res Treat; 2011 Jun; 127(3):659-69. PubMed ID: 20635137
[TBL] [Abstract][Full Text] [Related]
7. GRB7 is required for triple-negative breast cancer cell invasion and survival.
Giricz O; Calvo V; Pero SC; Krag DN; Sparano JA; Kenny PA
Breast Cancer Res Treat; 2012 Jun; 133(2):607-15. PubMed ID: 22005836
[TBL] [Abstract][Full Text] [Related]
8. Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells.
Chan DW; Hui WW; Cai PC; Liu MX; Yung MM; Mak CS; Leung TH; Chan KK; Ngan HY
PLoS One; 2012; 7(12):e52578. PubMed ID: 23285101
[TBL] [Abstract][Full Text] [Related]
9. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo.
Sharpe R; Pearson A; Herrera-Abreu MT; Johnson D; Mackay A; Welti JC; Natrajan R; Reynolds AR; Reis-Filho JS; Ashworth A; Turner NC
Clin Cancer Res; 2011 Aug; 17(16):5275-86. PubMed ID: 21712446
[TBL] [Abstract][Full Text] [Related]
10. circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer.
Ling Y; Liang G; Lin Q; Fang X; Luo Q; Cen Y; Mehrpour M; Hamai A; Liu Z; Shi Y; Li J; Lin W; Jia S; Yang W; Liu Q; Song E; Li J; Gong C
Mol Cancer; 2022 Jan; 21(1):8. PubMed ID: 34980129
[TBL] [Abstract][Full Text] [Related]
11. [Knockdown of Grb7 inhibits growth of oral squamous cell carcinoma, cell proliferation and promoted apoptosis through ERK/FOXM1 pathway].
Liu BY; Cao G; Dong Z; Chen W; Xu JK; Zhang SL; Weng ZQ
Shanghai Kou Qiang Yi Xue; 2016 Dec; 25(6):688-693. PubMed ID: 28275791
[TBL] [Abstract][Full Text] [Related]
12. Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.
Nadler Y; González AM; Camp RL; Rimm DL; Kluger HM; Kluger Y
Ann Oncol; 2010 Mar; 21(3):466-473. PubMed ID: 19717535
[TBL] [Abstract][Full Text] [Related]
13. Upregulated GRB7 promotes proliferation and tumorigenesis of Bladder Cancer via Phospho-AKT Pathway.
Zheng Y; Pei Y; Yang L; Zeng Z; Wang J; Xie G; Wang L; Yuan J
Int J Biol Sci; 2020; 16(16):3221-3230. PubMed ID: 33162827
[TBL] [Abstract][Full Text] [Related]
14. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis.
Tanaka S; Pero SC; Taguchi K; Shimada M; Mori M; Krag DN; Arii S
J Natl Cancer Inst; 2006 Apr; 98(7):491-8. PubMed ID: 16595785
[TBL] [Abstract][Full Text] [Related]
15. Targeting the calmodulin-regulated ErbB/Grb7 signaling axis in cancer therapy.
Villalobo A; García-Palmero I; Stateva SR; Jellali K
J Pharm Pharm Sci; 2013; 16(2):177-89. PubMed ID: 23958188
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
[TBL] [Abstract][Full Text] [Related]
17. Constitutive NOTCH3 Signaling Promotes the Growth of Basal Breast Cancers.
Choy L; Hagenbeek TJ; Solon M; French D; Finkle D; Shelton A; Venook R; Brauer MJ; Siebel CW
Cancer Res; 2017 Mar; 77(6):1439-1452. PubMed ID: 28108512
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
[TBL] [Abstract][Full Text] [Related]
19. Context-dependent role of Grb7 in HER2+ve and triple-negative breast cancer cell lines.
Lim RC; Price JT; Wilce JA
Breast Cancer Res Treat; 2014 Feb; 143(3):593-603. PubMed ID: 24464577
[TBL] [Abstract][Full Text] [Related]
20. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
